|
|
|
28.07.26 - 19:54
|
GSK heads to Cambridge with long-awaited positive vibes | Nils Pratley (The Guardian)
|
|
|
Pharmaceutical company's move to new £400m research centre accompanied by encouraging news for shareholders“A vote of confidence in British business,” trumpeted Andy Burnham, seizing the political gift of GSK splashing out £400m on a shiny new research and development centre in Cambridge.For positive vibes, it definitely beats the early pharma news his predecessor as prime minister received. That was the painful tale of how AstraZeneca, frustrated by indecision in the Treasury, cancelled its intended £450m expansion of a vaccine plant in Speke in Liverpool. Continue reading......
|
|
|
|
|
|
|
|
|
28.07.26 - 16:24
|
GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development (The Guardian)
|
|
|
Pharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D siteBusiness live – latest updatesThe British drugmaker GSK is to announce sweeping job cuts as part of a £1.9bn cost-cutting programme to pay for a £400m investment in UK life sciences over the next three years, including in a new research and development centre in Cambridge, as it looks to develop drugs more quickly under its new chief executive.The pharmaceuticals company announced on Tuesday it will move more than 1,000 of its scientists to its new site on the Cambridge biomedical campus. It will close its R&D site in Stevenage in Hertfordshire by 2029, while upgrading its R&D laboratories at nearby Ware and moving some employees there. Continue reading......
|
|
|
28.07.26 - 16:00
|
GSK Underweight (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für GSK nach Zahlen auf "Underweight" mit einem Kursziel von 1700 Pence belassen. Der Pharmakonzern habe umsatz- und gewinnseitig die Erwartungen übertroffen, schrieb Zain Ebrahim in ......
|
|
|
28.07.26 - 16:00
|
GSK Outperform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für GSK nach Zahlen zum zweiten Quartal auf "Outperform" mit einem Kursziel von 2825 Pence belassen. Der britische Pharmakonzern habe die Markterwartung mit Blick auf ......
|
|
|
|
|
28.07.26 - 15:45
|
GSK Buy (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für GSK nach Quartalszahlen auf "Buy" mit einem Kursziel von 2500 Pence belassen. Der Umsatz habe die Konsensschätzung etwas übertroffen, angeführt von unerwartet starken Erlösen ......
|
|
|
28.07.26 - 15:16
|
GSK Aktie: Starke Q2-Zahlen - Investitionen in Pipeline angekündigt (Aktiencheck)
|
|
|
Wien (www.aktiencheck.de) - GSK-Aktienanalyse von der Raiffeisen Bank International AG:
Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI), nimmt die Aktie von GSK plc (ISIN: GB00BN7SWP63, WKN: A3DMB5, Ticker-Symbol: GS71, London Stock Exchange-Symbol: GSK, NASDAQ OTC-Symbol: GLAXF) unter die Lupe. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
